Multimodal Assessment of Tumor Metabolism
In this study with the Norlux Laboratory of Neuro-oncology of Pr. Simone Niclou of the LIH, and in collaboration with the University of Bergen, Norway, we have used PET imaging and Magnetic Resonance Spectroscopy (MRS) to assess the metabolic changes induced by antiangiogenic therapy in glioblastomas (GBM)1. PET imaging with radiotracers 18F-FDG and 18F-FMISO was used to probe glucose consumption and hypoxia in rat models of GBM.
MRS was used to assess the concentration of the most abundant metabolites in the brain and in tumors. Absolute quantification in LC Model of metabolites concentration measured in vivo revealed a substantial increase in lactate after anti-angiogenic therapy, a finding that was confirmed by metabolomic analysis of tissues samples.